NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $101.90 -0.97 (-0.94 %) (As of 07/20/2018 04:00 PM ET)Previous Close$101.90Today's Range$101.33 - $103.062752-Week Range$75.81 - $104.46Volume1.04 million shsAverage Volume1.13 million shsMarket Capitalization$18.18 billionP/E Ratio-152.09Dividend YieldN/ABeta1.66 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California. Receive BMRN News and Ratings via Email Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:BMRN CUSIP09061G10 Webwww.bmrn.com Phone415-506-6700 Debt Debt-to-Equity Ratio0.29 Current Ratio2.90 Quick Ratio2.29 Price-To-Earnings Trailing P/E Ratio-152.09 Forward P/E Ratio-849.17 P/E GrowthN/A Sales & Book Value Annual Sales$1.31 billion Price / Sales13.71 Cash FlowN/A Price / CashN/A Book Value$15.99 per share Price / Book6.37 Profitability EPS (Most Recent Fiscal Year)($0.67) Net Income$-117,040,000.00 Net Margins-10.48% Return on Equity-3.01% Return on Assets-1.89% Miscellaneous Employees2,581 Outstanding Shares176,710,000Market Cap$18,178.50 BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions What is BioMarin Pharmaceutical's stock symbol? BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN." How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Wednesday, April, 25th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.08. The biotechnology company had revenue of $373.45 million for the quarter, compared to analyst estimates of $348.73 million. BioMarin Pharmaceutical had a negative net margin of 10.48% and a negative return on equity of 3.01%. The firm's revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.20 EPS. View BioMarin Pharmaceutical's Earnings History. When is BioMarin Pharmaceutical's next earnings date? BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for BioMarin Pharmaceutical. What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $0.57-0.79 for the period, compared to the Thomson Reuters consensus estimate of $0.70. The company issued revenue guidance of $1.47-1.53 billion, compared to the consensus revenue estimate of $1.49 billion. What price target have analysts set for BMRN? 20 brokers have issued 12 month target prices for BioMarin Pharmaceutical's stock. Their forecasts range from $92.00 to $145.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $113.6842 in the next year. This suggests a possible upside of 11.6% from the stock's current price. View Analyst Ratings for BioMarin Pharmaceutical. What is the consensus analysts' recommendation for BioMarin Pharmaceutical? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 4 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about BioMarin Pharmaceutical stock? Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock: 1. According to Zacks Investment Research, "BioMarin reported lower-than-expected earnings in Q1 but beat estimates for sales. BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, backed by strong underlying patient demand trends. BioMarin expects sustained growth in both the drugs. The latest FDA approval of pegvaliase was the second product approval for BioMarin in less than two years, the first being Brineura in mid-2017. Its impressive rare disease pipeline is also progressing well. However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries, mainly Brazil. The stock has outperformed the industry so far this year." (6/26/2018) 2. JPMorgan Chase & Co. analysts commented, "BMRN’s 4Q print was largely in-line; the company also provided 2018 guidance that bracketed consensus revenue expectations. There was some incremental color on regulatory (pegvaliase) and commercial (Brineura/pegvaliase) progress / expectations for emerging products. Importantly, the pipeline continues on track, and 2019 looks to be a critical year on that front. We anticipate interest in BMRN will increase materially as we eventually get closer to the pivotal data for val rox and vosoritide. Reiterate OW." (2/25/2018) Who are some of BioMarin Pharmaceutical's key competitors? Some companies that are related to BioMarin Pharmaceutical include Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), UCB (UCBJF), GRIFOLS S A/S (GRFS) and Merck KGaA (MKGAF). Who are BioMarin Pharmaceutical's key executives? BioMarin Pharmaceutical's management team includes the folowing people: Mr. Jean-Jacques Bienaimé MBA, Chairman & CEO (Age 65)Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 59)Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 63)Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 56)Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 60) Has BioMarin Pharmaceutical been receiving favorable news coverage? News stories about BMRN stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioMarin Pharmaceutical earned a coverage optimism score of 0.07 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (1.07%), Fred Alger Management Inc. (0.55%), Scout Investments Inc. (0.12%), Bank of Montreal Can (0.06%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%) and Amalgamated Bank (0.01%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical. Which major investors are selling BioMarin Pharmaceutical stock? BMRN stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Capital One National Association and State of Alaska Department of Revenue. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical. Which major investors are buying BioMarin Pharmaceutical stock? BMRN stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Bank of Montreal Can, Fred Alger Management Inc., DnB Asset Management AS, Nisa Investment Advisors LLC, Verde Servicos Internacionais S.A., Gateway Investment Advisers LLC and CMH Wealth Management LLC. View Insider Buying and Selling for BioMarin Pharmaceutical. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioMarin Pharmaceutical's stock price today? One share of BMRN stock can currently be purchased for approximately $101.90. How big of a company is BioMarin Pharmaceutical? BioMarin Pharmaceutical has a market capitalization of $18.18 billion and generates $1.31 billion in revenue each year. The biotechnology company earns $-117,040,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. BioMarin Pharmaceutical employs 2,581 workers across the globe. How can I contact BioMarin Pharmaceutical? BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected] MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 995 (Vote Outperform)Underperform Votes: 504 (Vote Underperform)Total Votes: 1,499MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?